FDA's Special Relationship with NEJM
This article was originally published in RPM Report
Under Commissioner Hamburg, the New England Journal of Medicine has been a common vehicle for the agency’s public health messages. Here is the back story.
You may also be interested in...
Physicians and patients need a better understanding of the quality of clinical trial design and data used to approve drugs, say researchers in a study published in JAMA. That led them to suggest a grading system to add another layer of information to FDA approvals, adding another academic suggestion for elaborating, explaining and embellishing FDA action.
Avandia and Meridia are different drugs with parallel regulatory histories: both are long-marketed treatments for metabolic disease. Both have an increased risk of cardiovascular events. And both were considered for withdrawal at roughly the same time by the same FDA division. But while there were many similarities between the two, the reviews were markedly different with markedly different outcomes.
FDA is weighing whether to pull GlaxoSmithKline's Avandia and Abbott Laboratories' Meridia off the market. Past examples demonstrate the final decision on whether to remove a drug or keep it on the market is a messy process made by a select number of government officials.